Skip to main content

Table 4 Adverse events of any grade seen in > 5% of patients in either protocol arm

From: TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer

 Letrozole, n = 25Letrozole/Bevacizumab, n = 50
 Number of patients (percent)
Adverse eventsAny gradeGrade ≥ 3Any gradeGrade ≥ 3
 Hot flashes7 (28)09 (18)0
 Arthralgia/joint stiffness6 (24)2 (8)13 (26)2 (4)
 Fatigue4 (16)07 (14)1 (2)
 Myalgias/cramps3 (12)03 (6)0
 Nausea/vomiting2 (8)01 (2)0
 Night sweats2 (8)02 (4)0
 Mood swings/anxiety/agitation1 (4)03 (6)0
 Vaginal dryness1 (4)03 (6)0
 Hypertension1 (4)016 (32)4 (8)
 Hemorrhagic and thrombotic events008 (16)3 (6)
 Headache1 (4)07 (14)0
 Proteinuria005 (10)2 (4)
 Dyspnea1 (4)05 (10)0
 Skin (rash, discoloration, pruritus)2 (8)04 (8)0
 Lower extremity edema003 (6)0